TY - JOUR
T1 - Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults
AU - Kurella Tamura, Manjula
AU - Pajewski, Nicholas M.
AU - Bryan, R. Nick
AU - Weiner, Daniel E.
AU - Diamond, Matthew
AU - Van Buren, Peter
AU - Taylor, Addison
AU - Beddhu, Srinivasan
AU - Rosendorff, Clive
AU - Jahanian, Hesamoddin
AU - Zaharchuk, Greg
N1 - Funding Information:
The Systolic Blood Pressure Intervention Trial is funded with Federal funds from the NIH, including the National Heart, Lung, and Blood Institute (NHLBI), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute on Aging (NIA), and the National Institute of Neurological Disorders and Stroke (NINDS), under contract numbers HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, HHSN268200900049C, and Inter-Agency Agreement Number A-HL-13-002-001. It was also supported in part by resources and use of facilities through the Department of Veterans Affairs. The SPRINT investigators acknowledge the contribution of study medications (azilsartan and azilsartan combined with chlorthalidone) from Takeda Pharmaceuticals International Inc. All components of the SPRINT study protocol were designed and implemented by the investigators. The investigative team collected, analyzed, and interpreted the data. All aspects of manuscript writing and revision were carried out by the coauthors. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, the US Department of Veterans Affairs, or the US government. For a full list of contributors to SPRINT, please see the supplementary acknowledgement list. ClinicalTrials.gov Identifier: NCT01206062. MIND the Kidneys is funded by R01 DK092241 from the National Institute of Diabetes and Digestive and Kidney Diseases. Also supported by the following CTSAs funded by NCATS: CWRU: UL1TR000439; OSU: UL1RR025755; University of Pennsylvania: UL1RR024134 and UL1TR000003; Boston: UL1RR025771; Stanford: UL1TR000093; Tufts: UL1RR025752, UL1TR000073, and UL1TR001064; University of Illinois: UL1TR000050; University of Pittsburgh: UL1TR000005; UT Southwestern: 9U54TR000017-06; University of Utah: UL1TR00010505; Vanderbilt University: UL1 TR000445; George Washington University: UL1TR000075; University of California, Davis: UL1 TR000002; University of Florida: UL1 TR000064; University of Michigan: UL1TR000433; Tulane University: P30GM103337; COBRE Award NIGMS; SPRINT.
Publisher Copyright:
© 2016 American Academy of Neurology.
PY - 2016/3/29
Y1 - 2016/3/29
N2 - Objective: To determine the relation between markers of kidney disease - estimated glomerular filtration rate (eGFR) and urine albumin to creatinine ratio (UACR) - with cerebral blood flow (CBF) and white matter volume (WMV) in hypertensive adults. Methods: We used baseline data collected from 665 nondiabetic hypertensive adults aged ≥50 years participating in the Systolic Blood Pressure Intervention Trial (SPRINT). We used arterial spin labeling to measure CBF and structural 3T images to segment tissue into normal and abnormal WMV. We used quantile regression to estimate the association between eGFR and UACR with CBF and abnormal WMV, adjusting for sociodemographic and clinical characteristics. Results: There were 218 participants (33%) with eGFR <60 mL/min/1.73 m 2 and 146 participants (22%) with UACR ≥30 mg/g. Reduced eGFR was independently associated with higher adjusted median CBF, but not with abnormal WMV. Conversely, in adjusted analyses, there was a linear independent association between UACR and larger abnormal WMV, but not with CBF. Compared to participants with neither marker of CKD (eGFR ≥60 mL/min/1.73 m 2 and UACR <30 mg/g), median CBF was 5.03 mL/100 g/min higher (95% confidence interval [CI] 0.78, 9.29) and abnormal WMV was 0.63 cm 3 larger (95% CI 0.08, 1.17) among participants with both markers of CKD (eGFR <60 mL/min/1.73 m 2 and UACR ≥30 mg/g). Conclusions: Among nondiabetic hypertensive adults, reduced eGFR was associated with higher CBF and higher UACR was associated with larger abnormal WMV.
AB - Objective: To determine the relation between markers of kidney disease - estimated glomerular filtration rate (eGFR) and urine albumin to creatinine ratio (UACR) - with cerebral blood flow (CBF) and white matter volume (WMV) in hypertensive adults. Methods: We used baseline data collected from 665 nondiabetic hypertensive adults aged ≥50 years participating in the Systolic Blood Pressure Intervention Trial (SPRINT). We used arterial spin labeling to measure CBF and structural 3T images to segment tissue into normal and abnormal WMV. We used quantile regression to estimate the association between eGFR and UACR with CBF and abnormal WMV, adjusting for sociodemographic and clinical characteristics. Results: There were 218 participants (33%) with eGFR <60 mL/min/1.73 m 2 and 146 participants (22%) with UACR ≥30 mg/g. Reduced eGFR was independently associated with higher adjusted median CBF, but not with abnormal WMV. Conversely, in adjusted analyses, there was a linear independent association between UACR and larger abnormal WMV, but not with CBF. Compared to participants with neither marker of CKD (eGFR ≥60 mL/min/1.73 m 2 and UACR <30 mg/g), median CBF was 5.03 mL/100 g/min higher (95% confidence interval [CI] 0.78, 9.29) and abnormal WMV was 0.63 cm 3 larger (95% CI 0.08, 1.17) among participants with both markers of CKD (eGFR <60 mL/min/1.73 m 2 and UACR ≥30 mg/g). Conclusions: Among nondiabetic hypertensive adults, reduced eGFR was associated with higher CBF and higher UACR was associated with larger abnormal WMV.
UR - http://www.scopus.com/inward/record.url?scp=84962866798&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000002527
DO - 10.1212/WNL.0000000000002527
M3 - Article
C2 - 26920359
AN - SCOPUS:84962866798
SN - 0028-3878
VL - 86
SP - 1208
EP - 1216
JO - Neurology
JF - Neurology
IS - 13
ER -